AdCurrently available treatments fall short in treating patients with RAS-addicted PDAC. Given its pivotal role in PDAC, RAS has strong potential to be a therapeutic target.

AdIndicated for NF1 patients aged 2-18 with symptomatic, inoperable plexiform neurofibromas. Learn how your patients can potentially benefit from this NF1 PN treatment.